Long-term macrolide therapy in chronic inflammatory airway diseases

被引:97
作者
Crosbie, P. A. J. [1 ]
Woodhead, M. A. [1 ]
机构
[1] Manchester Royal Infirm, Dept Resp Med, Manchester M13 9WH, Lancs, England
关键词
Airway; anti-inflammatory; ketolide; macrolide; BRONCHIOLITIS OBLITERANS SYNDROME; LOW-DOSE ERYTHROMYCIN; BRONCHIAL HYPERRESPONSIVENESS; CYSTIC-FIBROSIS; DOUBLE-BLIND; QT PROLONGATION; DIFFUSE PANBRONCHIOLITIS; CHLAMYDIA-PNEUMONIAE; VENTRICULAR-TACHYCARDIA; PSEUDOMONAS-AERUGINOSA;
D O I
10.1183/09031936.00042208
中图分类号
R56 [呼吸系及胸部疾病];
学科分类号
摘要
In addition to direct antibacterial actions, 14- and 15-member-ring macrolides have immune modulating effects that appear to be the reason for clinical benefit in diffuse panbronchiolitis. A literature search was conducted for studies of the clinical effectiveness of macrolides in other chronic lung conditions. A number of studies were identified that showed short-term beneficial outcomes or the potential for such outcomes in cystic fibrosis, bronchiectasis, chronic obstructive pulmonary disease, asthma and post-transplant obliterative bronchiolitis. The studies were limited by small patient numbers, different outcome measures and short-term follow-up, and were not designed to assess potentially harmful effects. Further large prospective and long-term studies are required in order to identify potential benefit and harm before these agents can be recommended routinely for these conditions.
引用
收藏
页码:171 / 181
页数:11
相关论文
共 87 条
  • [11] Generating signals of drug-adverse effects from prescription databases and application to the risk of arrhythmia associated with antibacterials
    Corrao, G
    Botteri, E
    Bagnardi, V
    Zambon, A
    Carobbio, A
    Falcone, C
    Leoni, O
    [J]. PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2005, 14 (01) : 31 - 40
  • [12] Cymbala Alicia A, 2005, Treat Respir Med, V4, P117, DOI 10.2165/00151829-200504020-00005
  • [13] The role of atypical organisms in asthma
    Daian, CM
    Wolff, AH
    Bielory, L
    [J]. ALLERGY AND ASTHMA PROCEEDINGS, 2000, 21 (02) : 107 - 111
  • [14] Macrolide resistance in bacteremic pneumococcal disease: Implications for patient management
    Daneman, N.
    McGeer, A.
    Green, K.
    Low, D. E.
    [J]. CLINICAL INFECTIOUS DISEASES, 2006, 43 (04) : 432 - 438
  • [15] Davies G, 2004, THORAX, V59, P540
  • [16] Molecular mechanisms of anti-inflammatory action of erythromycin in human bronchial epithelial cells:: Possible role in the signaling pathway that regulates nuclear factor-κB activation
    Desaki, M
    Okazaki, H
    Sunazuka, T
    Omura, S
    Yamamoto, K
    Takizawa, H
    [J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2004, 48 (05) : 1581 - 1585
  • [17] Effect of azithromycin on the severity of bronchial hyperresponsiveness in patients with mild asthma
    Ekici, A
    Ekici, M
    Erdemoglu, AK
    [J]. JOURNAL OF ASTHMA, 2002, 39 (02) : 181 - 185
  • [18] Long term azithromycin in children with cystic fibrosis: a randomised, placebo-controlled crossover trial
    Equi, A
    Balfour-Lynn, IM
    Bush, A
    Rosenthal, M
    [J]. LANCET, 2002, 360 (9338) : 978 - 984
  • [19] Fecik RA, 2005, CURR OPIN DRUG DISC, V8, P741
  • [20] LONG-TERM EFFECT OF ERYTHROMYCIN THERAPY IN PATIENTS WITH CHRONIC PSEUDOMONAS-AERUGINOSA INFECTION
    FUJII, T
    KADOTA, J
    KAWAKAMI, K
    IIDA, K
    SHIRAI, R
    KASEDA, M
    KAWAMOTO, S
    KOHNO, S
    [J]. THORAX, 1995, 50 (12) : 1246 - 1252